Aditi Shastri

https://assets.montefioreeinstein.org/profiles/images/Shastri_Aditi_2x.jpg

First Name

Aditi

Last Name

Shastri

NPI

1568797058

Faculty ID

14819

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>I am a board certified hematologist and medical oncologist. I specialize in caring for patients with hematologic malignancies and specifically myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and aplastic anemia (AA).</p>
<p>I have a strong interest in exploring novel treatment approaches for myelodysplatic syndromes (MDS) and Acute Myeloid Leukemia (AML) after the failure of therapy with hypomethylating agents. I specifically focus on therapeutically targetting the transcription factor STAT3 in MDS and AML.</p>
<p>My research was previously funded through the NIH Paul Calabresi Career Development Award (K12) &amp; currently through the Leukemia Lymphoma Society (LLS)-TRP Award &amp; MDS Foundation Gilbert Bruce Smith Young Investigator Award.</p>
<p>My original research and reviews have been published in leading peer reviewed journals that include Blood, JCI, Nature Reviews Cancer &amp; Lancet Hematology.&nbsp; I have been an invited speaker at several conferences and forums nationally as well as internationally.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Lab Website Link

EMR ID

57152

Is Open Scheduling

Off

Adarsha Selvachandran

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b851f490-5fb9-11ec-9773-d197dc92a0d8.jpg

First Name

Adarsha

Last Name

Selvachandran

NPI

1134578248

Faculty ID

16723

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

87590

Is Open Scheduling

Off

Jonathan M. Schwartz

https://assets.montefioreeinstein.org/profiles/images/Schwartz_Jonathan_MD_2x.jpg

First Name

Jonathan

Last Name

Schwartz

NPI

1215945738

Faculty ID

648

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Jonathan M. Schwartz is a board Certified Transplant Hepatologist. &nbsp;He is a graduate of Tel Aviv University, Sackler School of Medicine. He was an Internal Medicine Resident at Albert Einstein College of Medicine and a Fellow in Gastroenterology/Transplant Hepatology at the University of Washington in Seattle. &nbsp;He returned to New York in 2011 from Portland, Oregon where he served as an Associate Professor of Medicine at Oregon Health and Sciences University.</p>
<p>Dr. &nbsp;Schwartz has an interest in treating patients with acute and chronic liver diseases including those patients with advanced liver diseases who require liver transplantation.</p>
<p>He has a special interest in the multidisciplinary care of patients with liver tumors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong><br /></strong></p>
<ul>
<li>Estes JD, Stolpman D, Olyaei A, Ham JM, <strong>Schwartz JM</strong>, Orloff SL.&nbsp; High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Fulminant Hepatic Failure Patients. Arch Surg. 2003;138(8):852-8.</li>
<li><strong>Schwartz JM</strong>, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman D, Kowdley KV.&nbsp; Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure. J Clin Gastroenterol 2004;38(7):590-594.</li>
<li>Lim LL, Scarborough J, Thorne J, Graham E, Kempen J, Mackensen F, Nguyen Q D, Prabriputaloong T, Read R, Suhler EB, <strong>Schwartz JM</strong>, &nbsp;Smith JR. Uveitis in Patients with Autoimmune Hepatitis. Am J Ophthalmol. 2009;147(2):332-338.</li>
<li>O&rsquo;Glasser AY, Scott DA, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, and <strong>Schwartz JM.</strong>Hepatic and Cardiac Iron Overload Among Patients with End-Stage Liver Disease Referred for Liver Transplantation. Clinical Transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51.</li>
<li>Kanwal F, Befeler A, Chari R, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, <strong>Schwartz J</strong>, Van Thiel D, Hassanein TI, Li J, Zeringue A, DiBisceglie A. Rate of Potentially Curative Treatment in Patients with Hepatocellular Carcinoma.&nbsp; Aliment Pharmacol Ther. 2012 Aug;36(3):257-65.</li>
<li>Bichoupan K1,&nbsp;<strong>Schwartz JM,</strong>&nbsp;Martel-Laferriere V,&nbsp;Giannattasio ER,&nbsp;Marfo K,&nbsp;Odin JA,&nbsp;Liu LU,&nbsp;Schiano TD,&nbsp;Perumalswami P,&nbsp;Bansal M,&nbsp;Gaglio PJ,&nbsp;Kalia H,Dieterich DT,&nbsp;Branch AD,&nbsp;Reinus JF. Effect of Fibrosis on Adverse Events in Patients with Hepatitis C Treated with Telaprevir. Aliment Pharmacol Ther.&nbsp;2014;39(2):209-16.</li>
<li><strong>Schwartz J</strong> and Carithers RL.&nbsp; Epidemiology and Etiologic Associations of Primary Hepatocellular Carcinoma.&nbsp; In Rose BD, editor. Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li><strong>Schwartz JM </strong>and Carithers RL, Jr.&nbsp; Clinical features, diagnosis, and screening for primary hepatocellular carcinoma.&nbsp; Up to date in Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Curley SA, Stewart KE, <strong>Schwartz JM</strong>, Carthers RL, Jr.&nbsp; Nonsurgical therapies for localized hepatocellular carcinoma.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.<strong>&nbsp;</strong></li>
<li><strong>Schwartz JM</strong>.&nbsp; Approach to the patient with a focal liver lesion.&nbsp; Up to date Inc Gastroenterology and Hepatology.&nbsp; Up to date, Inc. Wellesley, MA, Updated 2014.</li>
<li>Hartwell L and <strong>Schwartz JM.&nbsp; </strong>AsymptomaticLiver Chemistry Abnormalities. Journal of Clinical Outcomes Management. 2009; 16 (11): 525-34.</li>
<li>Urquhart J<strong>, Schwartz, JM.</strong> Hepatocellular Carcinoma Surveillance in a Western Population with Hepatitis B. Current Hepatitis Reports, 2011.</li>
<li><strong>Schwartz, JM </strong>and Reinus JF.&nbsp; Prevalence and Natural History of Alcoholic Liver Disease.&nbsp; Clinics in Liver Disease. 2012; 16 (4): 659-66.</li>
</ul>
<p>&nbsp;</p>

EMR ID

3842

Is Open Scheduling

Off

Scott J. Schafler

https://assets.montefioreeinstein.org/profiles/images/Scott-Schafler.jpg

First Name

Scott

Last Name

Schafler

NPI

1417219585

Faculty ID

16440

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55639

Is Open Scheduling

Off

Jayanta Roy-Chowdhury

https://assets.montefioreeinstein.org/profiles/images/3063-jayanta-roy-chowdhury.jpg

First Name

Jayanta

Last Name

Roy-Chowdhury

NPI

1669561908

Faculty ID

3063

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal"><strong><em>Key Words: &nbsp;Liver, Inherited liver diseases; Cell and Gene Therapy</em></strong></p>
<p class="MsoNormal" style="margin-bottom: 6.0pt; line-height: normal;">&nbsp;</p>
<p style="margin: 0px 0px 8px; text-indent: 0.5in;"><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">Our current focus is on developing cell and gene-based therapies for monogenic liver diseases, such as inherited hyperbilirubinemia (Crigler-Najjar syndrome, CN-1), </span><span style="margin: 0px; font-family: Symbol; font-size: 9pt;">a</span>_{<span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">1</span>}<span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;"> antitrypsin (AAT) deficiency, dyslipidemias and hemophilias A and B.</span></p>
<p style="margin: 0px; text-indent: 0.5in;"><strong><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">&nbsp;Subproject 1.</span></strong><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">&nbsp; <strong>Hepatocyte-based therapies for genetic liver diseases.</strong>&nbsp; To develop a minimally invasive alternative to liver transplantation, we are developing strategies to repopulate the liver by transplanted hepatocytes. To overcome the hurdles of inefficient hepatocyte engraftment and failure of transplanted hepatocytes to proliferate, we are evaluating targeted hepatic irradiation and mitotic stimulation of the transplanted hepatocytes. Regiospecific conformal hepatic irradiation (HIR) is being used to transiently disrupt the sinusoidal endothelial barrier, thereby enhancing initial engraftment. HIR makes the host hepatocytes in the irradiated region less mitotically competent. We are exploring different types of mitotic agents to stimulate the proliferation of the engrafted hepatocytes, which can competitively repopulate the host liver. We are also evaluating whether co-transplantation of liver sinusoidal endothelial cells can augment liver repopulation by hepatocytes. Our work was translated into the first successful hepatocyte transplantation in a CN-1 patient, and more recently in two patients with urea cycle disorders and one with phenyl ketonuria.&nbsp; </span></p>
<p style="margin: 0px; text-indent: 0.5in;"><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">AAT deficiency (ATD) is one of the most common potentially lethal monogenic liver disorders in the West. In classic ATD, a mutant misfolded AAT (ATZ) tis secreted inefficiently and is retained within hepatocytes. Circulatory AAT deficiency leads to unrestrained neutrophil elastase activity in the lung, causing pulmonary emphysema, whereas ATZ accumulation within hepatocytes results liver disease. We showed that wildtype hepatocytes transplanted into transgenic mice expressing human ATZ competitively replace the host hepatocytes. Our current focus is to disrupt ATZ expression in a fraction of the hepatocyte mass by DNA break-enhanced homologous recombination in vivo, so that the gene-edited hepatocytes can repopulate the liver, thereby providing normal AAT and correcting the liver disease.</span></p>
<p style="margin: 0px; text-indent: 0.5in;"><strong><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">Subproject 2.</span></strong><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">&nbsp; <strong style="mso-bidi-font-weight: normal;">Transplantation of endothelial cells to repopulate mutant liver endothelial cells (LSEC): </strong>LSECs are highly specialized endothelial cells that are important in maintaining liver architecture, as well as hepatocyte regeneration and function. In addition, these cells express coagulation factor VIII (the deficiency of which causes hemophilia A) and Von Willebrand factor. In ongoing work, we have found that intravenous infusion of LSECs <span style="margin: 0px;">&nbsp;</span>following regional HIR results in engraftment of LSECs in the liver. Subsequent pharmacological stimulation of the LSECs results in regional liver repopulation by the transplanted cells. This procedure has cured the bleeding disorder in Factor VIII-deficient hemophilic mice. </span></p>
<p style="margin: 0px 0px 8px; text-indent: 0.5in;"><span style="margin: 0px; font-family: 'Arial',sans-serif; font-size: 9pt;">In ongoing studies we are correcting the genetic lesions in mutant hepatocytes and LSECs, using CRISPR-cas or zinc finger nuclease-enhanced homologous recombination to generate phenotypically corrected for transplantation into animal models of inherited human liver diseases. </span></p>
<p class="MsoNormal" style="margin-bottom: 6.0pt; line-height: normal;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong><span style="text-decoration: underline;">Recent Publications</span>:</strong></p>
<p style="background: #FEFEFE; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: black;">Ding J, Yannam GR, Roy-Chowdhury N, Hidvegi T, Basma H, Rennard SI, Wong RJ, Avsar Y, Guha C,Perlmutter DH, Fox IJ,<strong><span style="font-family: 'Arial',sans-serif;">&nbsp;Roy-Chowdhury J.&nbsp;</span></strong>Spontaneous hepatic repopulation in transgenic mice expressingmutant human alpha 1-anti-trypsin by wildtype donor hepatocytes. J. Clin. Invest. 121:1930-4, 2011.</span></p>
<p style="background: #FEFEFE; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Chen Y, Li Y, Wang X,&nbsp;&nbsp;Zhang W, Sauer V, Chang CJ, Han B, Tchaikovskaya T, Avsar Y, Tafaleng E, Madhusudana Girija S, Tar K, Stephen S, Bouhassira E, Guha C, Fox IJ,<strong><span style="font-family: 'Arial',sans-serif;">&nbsp;Roy-Chowdhury J</span></strong>&nbsp;and&nbsp;<strong><span style="font-family: 'Arial',sans-serif;">Roy-Chowdhury N</span></strong>. Amelioration of hyperbilirubinemia in Gunn rats after transplantation of hepatocytes derived from human induced pluripotent stem cells. Stem Cell Reports 5:1-9, 2015.</span></p>
<p style="background: #FEFEFE; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Sauer V,</span><span style="font-family: 'Arial',sans-serif; color: #373a3c;">&nbsp;</span><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Tchaikovskaya T, Wang X, Li Y, Zhang W Tar K, Polgar Z, Ding J, Guha C, Fox IJ,<strong><span style="font-family: 'Arial',sans-serif;">&nbsp;Roy-Chowdhury N, Roy-Chowdhury J.</span></strong>&nbsp;Human urinary epithelial cells as a source of engraftable hepatocyte-like cells using stem cell technology. Cell transplant, 2016, 25:2221-2243.</span></p>
<p style="background: #FEFEFE; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Soltys KA, Setoyama K, Tafaleng EN, et al.&nbsp;</span><a href="https://www.ncbi.nlm.nih.gov/pubmed/28027971"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif;">Host conditioning and rejection monitoring in hepatocyte transplantation in humans.</span></a><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">&nbsp;J Hepatol. 66:987-1000, 2017. doi: 10.1016/j.jhep.2016.12.017.&nbsp;&nbsp;PMID: 28027971.</span></p>
<p style="background: #FEFEFE; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Peterson EA, Polgar Z, Devakanmalai GS, Li Y, Jaber FL, Zhang W, Wang X, Iqbal NJ, Murray JW, Roy-Chowdhury N, Quispe Tintaya W, Maslov AY, Tchaikovskaya TL, Sharma Y, Rogler LE, Gupta S, Zhu L<strong><span style="font-family: 'Arial',sans-serif;">, Roy-Chowdhury J</span></strong>, Shafritz DA. Genes and pathways promoting long-term liver repopulation by ex vivo hYAP-ERT2 transduced hepatcytes and treatment of jaundice Gunn rats. Hepatology Communications 2019; 3:129-146</span></p>
<p style="text-align: justify; background: white; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c; background: white;">Barahman M, Zhang W, Harris HY, Aiyer A, Kabarriti R, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS,&nbsp;<strong><span style="font-family: 'Arial',sans-serif;">Roy-Chowdhury J</span></strong>, Asp P,&nbsp;&nbsp;Guha C.&nbsp;</span><a href="https://www.sciencedirect.com/science/article/pii/S0168827819300224&quot; target="_blank" rel="noopener"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; background: white;">Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.</span><span style="font-family: 'Arial',sans-serif;">&nbsp;</span><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif;">J Hepatol. 2019 70:1170-1179.</span></a></p>
<p style="text-align: justify; background: white; margin: 0in 0in 3.0pt 0in;"><span style="font-size: 9.0pt; font-family: 'Arial',sans-serif; color: #373a3c;">Li Y, Guha C, Asp P, Wang X, Tchaikovskya TL, Kim K, Mendel M, Cost GJ, Perlmutter DH, Roy-Chowdhury N, Fox IJ, Conway A, <strong>Roy-Chowdhury J</strong>. Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human &alpha;1-antitrypsin deficiency. Hepatol Commun. 2023 Feb 27;7(3):e0070. PMCID: PMC9974076.</span></p>

EMR ID

3232

Is Open Scheduling

Off

John F. Reinus

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/af2bc270-3a87-11ed-8158-59ecbd24247c.jpg

First Name

John

Last Name

Reinus

NPI

1669557435

Faculty ID

2404

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<FONT color=#000000>Clinical practice limited to liver diseases.&nbsp; Research on liver diseases and related topics.</FONT>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

Selected Publications

<p>&nbsp;</p>
<ol>
<li>Gaglio P, Moss N, McGaw C, Reinus JF. Direct-acting antiviral therapy for hepatitis C: Attitudes regarding future use. Dig Dis Sci. 2011; 56:1509-1515.</li>
<li>Flattau A, Olaywi M, Gaglio PJ, Marcus P, Meissner P, L Dorfman EB, Reinus JF. Social barriers to listing for adult liver transplantation: Their prevalence and association with program characteristics. Liver Transpl. 2011; 17:1167-1175.</li>
<li>Golowa YS, Cynamon J, Reinus JF, Kinkhabwala M, Abrams M, Jagust M, Chernyak V, Kaubisch A. Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads. J Vasc Interv Radiol. 2012; 23:1031-1035.</li>
<li>Schwartz JM, Reinus JF. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis. 2012; 16:659-666. Review.</li>
<li>Kinkhabwala M, Lindower J, Reinus JF, Principe AL, Gaglio PJ. Expedited liver allocation in the United States: a critical analysis. Liver Transpl. 2013; 19: 1159-1165.</li>
<li>Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther. 2014; 39:209-216.</li>
<li>Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF. Limited fibrosis progression but significant mortality in patients ineligible for interferon-based hepatitis C therapy.&nbsp; J Clin Exp Hepatol. 2016 Jun;6(2):100-8.</li>
<li>Chacko KR, Reinus J.&nbsp; Spectrum of alcoholic liver disease.&nbsp; Clin Liver Dis. 2016 Aug;20(3):419-27.</li>
<li>Chacko KR, Reinus J. Extrahepatic complications of nonalcoholic fatty liver disease.&nbsp; Clin Liver Dis. 2016 May;20(2):387-401. Review.</li>
</ol>
<p>&nbsp;</p>

EMR ID

3634

Biography

<p>John F. Reinus, MD, is Emeritus Medical Director, Liver Transplantation and Professor, Medicine at Montefiore Einstein. His work centers on liver transplantation, end-stage liver disease and viral hepatitis.</p><p>Dr. Reinus studied Pre-Medical Sciences at Columbia University before earning his Doctor of Medicine at Cornell Medical College in 1981. He then began an internal medicine internship at Bellevue Hospital Center, completing it in 1982. Following this, Dr. Reinus completed a residency in internal medicine at the same institution in 1984 before completing a hepatology fellowship at Emory University School of Medicine in 1985. He went on to complete a fellowship in gastroenterology at the same institution, finishing it in 1987. Dr. Reinus then completed a Transplant Hepatology Preceptorship at the Center for Liver Disease and Transplantation in 2006.</p><p>Building on his clinical focus, Dr. Reinus&rsquo; research is focused on liver diseases and related topics. His work has been published in peer-reviewed journals, books, chapters, reviews and abstracts, and he has presented at numerous conferences and meetings.</p><p>Dr. Reinus is board certified by the American Board of Medical Examiners in Internal Medicine, Gastroenterology and Transplant Hepatology. He is a fellow of the American Association for the Study of Liver Diseases and a member of the American Gastroenterological Association and the American Society of Transplantation.</p>

Is Open Scheduling

Off

Mark A. Ramirez

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ramirez_Mark_MD.jpg

First Name

Mark

Last Name

Ramirez

NPI

1467494336

Faculty ID

3064

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3582

Is Open Scheduling

Off

Debra H. Pan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8ad08ab0-c473-11ee-87a1-7535ccaad089.jpg

First Name

Debra

Last Name

Pan

NPI

1679659510

Faculty ID

10100

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

4747

Biography

<!--Dr. Pan graduated from Soochow University School of Medicine in China, and completed her Pediatric Residency at Long Island College Hospital, and her Pediatric Gastroenterology and Nutrition Fellowship at The Mount Sinai Hospital in New York City. She specializes in viral hepatitis, inflammatory bowel disease, acid reflux, celiac disease, tube feeding, nutrition and endoscopies.--><p>Debra H. Pan, MD, MS, is an Attending Physician in the Division of Gastroenterology, Hepatology, and Nutrition at Children's Hospital at Montefiore (CHAM) and an Associate Professor of Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is on pediatric gastrointestinal and liver conditions such as inflammatory bowel disease, acid reflux, Helicobacter pylori gastritis, tube feeding, endoscopy, cholestasis, viral hepatitis, autoimmune hepatitis, and liver transplant. </p><p>A graduate from Soochow University School of Medicine in China in 1983, Dr. Pan received her Master of Science in Cardiac Electrophysiology from the same institute in 1989. From 1991 to 2000, she completed a postdoctoral research fellowship in Pharmacology and Toxicology at Michigan State University for 2 years and then continued gastrointestinal research at Columbia University. She completed her Pediatric residency at Long Island College Hospital in 2003, and her Pediatric Gastroenterology and Nutrition fellowship at Mount Sinai Hospital in New York City in 2005.</p><p>Dr. Pan's recent research focuses on the treatment outcomes of Helicobacter pylori infection and the natural history of the hepatitis B virus infection. Her work has been published in numerous peer-reviewed journals, books and review articles, and she is also an active journal reviewer for multiple journals.</p><p>Dr. Pan is a member of leading professional societies including North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), and the American Association for the Study of Liver Diseases. She is board certified by the American Board of Pediatrics in both General Pediatrics and Pediatric Gastroenterology and Nutrition.</p>

Is Open Scheduling

Off

Stuart Packer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0d90dcb0-3939-11ed-9b41-f32856b0701a.jpg

First Name

Stuart

Last Name

Packer

NPI

1124059621

Faculty ID

13484

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p>
<p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore&rsquo;s Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p>
<p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer, Clinical Cancer Research, British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer.

Elsevier Profile

EMR ID

5497

Biography

<p>Stuart Packer, MD, is a medical oncologist with extensive experience in treating lung, head and neck, prostate and other types of cancer. After graduating magna cum laude from Case Western Reserve University, Dr. Packer received his medical degree from the State University of New York/Downstate Medical Center. He went on to complete a residency in medicine and fellowship in hematology/medical oncology at Duke University Medical Center. Since then Dr. Packer has held clinical and teaching positions at leading cancer centers, including Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Montefiore Einstein Center for Cancer Care.</p><p>Dr. Packer&rsquo;s clinical expertise is in medical management of lung cancer, head and neck cancer and prostate cancer. He is director of the melanoma and sarcoma programs at Montefiore Einstein Center for Cancer Care. In addition, Dr. Packer is medical director of Montefiore's Oncology Care Model (OCM), an alternative payment model sponsored by the Centers for Medicare and Medicaid Services and aimed at improving patient care coordination and appropriateness of care.</p><p>Dr. Packer is the author or co-author of medical textbook chapter and articles in peer-reviewed journals, including <em>Cancer</em>, <em>Clinical Cancer Research</em>, <em>British Medical Journal</em> and <em>Lung Cancer</em>. He is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Is Open Scheduling

Off

Ann L. Nguyen

https://assets.montefioreeinstein.org/profiles/images/Nguyen_Ann_L_MD_2x_0.jpg

First Name

Ann

Last Name

Nguyen

NPI

1356510747

Faculty ID

12454

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Clinical Education in Neonatology</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Neonatal Medicine

Research Focus

Intestinal function and the treatment of fungal infections in infants.&nbsp;

Elsevier Profile

EMR ID

5377

Biography

<p>Dr. Ann Nguyen is a board-certified pediatrician and neonatologist who is a clinician specialist in neonatal medicine. She obtained her medical degree from Ross University School of Medicine and completed her training in pediatrics at the Children&rsquo;s Hospital at Albany Medical Center. Following an additional year as Pediatric Chief Resident, Dr. Nguyen completed a fellowship in neonatal-perinatal medicine at Mattel Children&rsquo;s Hospital, UCLA Medical Center. Dr. Nguyen&rsquo;s research interests include intestinal function and the treatment of fungal infections in infants. Dr. Nguyen is a certified instructor for the AAP-AHA Neonatal Resuscitation Program. </p>

Is Open Scheduling

Off